This “COVID-19 - Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The symptoms of COVID-19, caused by SARS-CoV-2, vary widely in severity, ranging from asymptomatic infection to severe respiratory illness. The most common symptoms include fever, dry cough, fatigue, and shortness of breath, often accompanied by sore throat, headache, and muscle aches. Many individuals also experience loss of taste or smell, which became a distinguishing feature of the disease. In some cases, gastrointestinal symptoms such as nausea, vomiting, and diarrhea may occur. Severe cases can progress to pneumonia, chest pain, confusion, and difficulty breathing, potentially leading to acute respiratory distress and multi-organ complications.
The pathophysiology of COVID-19 is driven by infection with SARS-CoV-2, a structurally complex virus containing spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. The spike protein plays a central role in disease initiation, where its receptor-binding domain attaches to ACE2 receptors expressed in the respiratory epithelium and multiple organs. Viral entry is facilitated by host proteases such as TMPRSS2, enabling membrane fusion and intracellular replication. In the early phase, viral replication causes direct cytopathic damage to infected tissues, particularly in the lungs. As the disease progresses, an exaggerated immune response is triggered, characterized by activation of immune cells and release of pro-inflammatory cytokines including IL-6, TNF-α, and interferon-γ. In severe cases, this leads to a “cytokine storm,” resulting in widespread systemic inflammation and tissue injury.
The etiology of COVID-19 is linked to infection with SARS-CoV-2, a betacoronavirus closely related to SARS-CoV and MERS-CoV. Genomic studies suggest a zoonotic origin, with bats as the primary reservoir and possible intermediate hosts such as pangolins before transmission to humans. The virus spreads mainly through respiratory droplets and aerosols during close contact, with minor contributions from contaminated surfaces and other routes. Mutations in the viral genome have led to multiple variants, such as Alpha, Delta, and Omicron, which enhance transmissibility and influence disease dynamics.
The diagnosis of COVID-19 primarily relies on detection of SARS-CoV-2 RNA using real-time PCR from nasopharyngeal or related specimens, which remains the gold standard due to its high specificity. Antigen tests provide faster results but are less sensitive, while serological tests are not recommended for diagnosing acute infection. Laboratory evaluations in hospitalized patients include blood counts, metabolic panels, inflammatory markers, and D-dimer levels to assess disease severity and guide management. Imaging modalities such as chest X-ray and CT scans may reveal characteristic findings like bilateral ground-glass opacities, although they are not definitive for diagnosis.
Treatment strategies depend on disease stage, targeting viral replication in early infection and immune dysregulation in later stages. Antiviral therapies such as Remdesivir, Nirmatrelvir (with ritonavir), and Molnupiravir are used in early or mild-to-moderate disease, particularly in high-risk patients. In hospitalized or severe cases, corticosteroids like Dexamethasone and immunomodulators such as Tocilizumab or baricitinib are recommended to control inflammation.
"COVID-19 - Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the COVID-19 pipeline landscape is provided which includes the disease overview and COVID-19 treatment guidelines. The assessment part of the report embraces, in depth COVID-19 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, COVID-19 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This product will be delivered within 2-4 business days.
COVID-19: Understanding
COVID-19: Overview
COVID-19 is a highly contagious viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has had a catastrophic effect on the world, resulting in more than 6 million deaths worldwide. Like other RNA viruses, SARS-CoV-2 adapts with genetic evolution and developing mutations. This results in mutant variants that may have different characteristics than their ancestral strains.The symptoms of COVID-19, caused by SARS-CoV-2, vary widely in severity, ranging from asymptomatic infection to severe respiratory illness. The most common symptoms include fever, dry cough, fatigue, and shortness of breath, often accompanied by sore throat, headache, and muscle aches. Many individuals also experience loss of taste or smell, which became a distinguishing feature of the disease. In some cases, gastrointestinal symptoms such as nausea, vomiting, and diarrhea may occur. Severe cases can progress to pneumonia, chest pain, confusion, and difficulty breathing, potentially leading to acute respiratory distress and multi-organ complications.
The pathophysiology of COVID-19 is driven by infection with SARS-CoV-2, a structurally complex virus containing spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins. The spike protein plays a central role in disease initiation, where its receptor-binding domain attaches to ACE2 receptors expressed in the respiratory epithelium and multiple organs. Viral entry is facilitated by host proteases such as TMPRSS2, enabling membrane fusion and intracellular replication. In the early phase, viral replication causes direct cytopathic damage to infected tissues, particularly in the lungs. As the disease progresses, an exaggerated immune response is triggered, characterized by activation of immune cells and release of pro-inflammatory cytokines including IL-6, TNF-α, and interferon-γ. In severe cases, this leads to a “cytokine storm,” resulting in widespread systemic inflammation and tissue injury.
The etiology of COVID-19 is linked to infection with SARS-CoV-2, a betacoronavirus closely related to SARS-CoV and MERS-CoV. Genomic studies suggest a zoonotic origin, with bats as the primary reservoir and possible intermediate hosts such as pangolins before transmission to humans. The virus spreads mainly through respiratory droplets and aerosols during close contact, with minor contributions from contaminated surfaces and other routes. Mutations in the viral genome have led to multiple variants, such as Alpha, Delta, and Omicron, which enhance transmissibility and influence disease dynamics.
The diagnosis of COVID-19 primarily relies on detection of SARS-CoV-2 RNA using real-time PCR from nasopharyngeal or related specimens, which remains the gold standard due to its high specificity. Antigen tests provide faster results but are less sensitive, while serological tests are not recommended for diagnosing acute infection. Laboratory evaluations in hospitalized patients include blood counts, metabolic panels, inflammatory markers, and D-dimer levels to assess disease severity and guide management. Imaging modalities such as chest X-ray and CT scans may reveal characteristic findings like bilateral ground-glass opacities, although they are not definitive for diagnosis.
Treatment strategies depend on disease stage, targeting viral replication in early infection and immune dysregulation in later stages. Antiviral therapies such as Remdesivir, Nirmatrelvir (with ritonavir), and Molnupiravir are used in early or mild-to-moderate disease, particularly in high-risk patients. In hospitalized or severe cases, corticosteroids like Dexamethasone and immunomodulators such as Tocilizumab or baricitinib are recommended to control inflammation.
"COVID-19 - Pipeline Insight, 2026" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the COVID-19 pipeline landscape is provided which includes the disease overview and COVID-19 treatment guidelines. The assessment part of the report embraces, in depth COVID-19 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, COVID-19 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence COVID-19 R&D. The therapies under development are focused on novel approaches to treat/improve COVID-19.COVID-19 Emerging Drugs Chapters
This segment of the COVID-19 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.COVID-19 Emerging Drugs
- VYD-2311: Invivyd, Inc.
- Ibuzatrelvir: Pfizer
- N-803: ImmunityBio, Inc.
- ENTVAX002: Entos Pharmaceuticals Inc.
- ALG-097558: Aligos Therapeutics
- RBM001: Rock BioMedical, Inc.
- MDX2301: OPKO Health, Inc.
- PA-001: PeptiDream Inc.
COVID-19: Therapeutic Assessment
This segment of the report provides insights about the different COVID-19 drugs segregated based on following parameters that define the scope of the report, such as:Major Players in COVID-19
- There are approx. 180+ key companies which are developing the therapies for COVID-19. The companies which have their COVID-19 drug candidates in the most advanced stage, i.e. Phase III include, Pfizer.
Phases
The report covers around 200+ products under different phases of clinical development like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
COVID-19 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Molecule Type
Products have been categorized under various Molecule types such as:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.COVID-19: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses COVID-19 therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 drugs.COVID-19 Report Insights
- COVID-19 Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
COVID-19 Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing COVID-19 drugs?
- How many COVID-19 drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of COVID-19?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the COVID-19 therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for COVID-19 and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Invivyd, Inc.
- Pfizer
- ImmunityBio, Inc.
- Entos Pharmaceuticals Inc.
- Rock BioMedical, Inc.
- OPKO Health, Inc.
- Lumen Bioscience, Inc.
- PeptiDream Inc.
- AstraZeneca
- HDT Bio
- Sanofi
- Imunon
- KBio Inc
- Enanta Pharmaceuticals, Inc
- Inflammx Therapeutics Inc
- Vaxart Inc
- BioVie Inc.
- AIM ImmunoTech Inc.
- CyanVac LLC
- Vasomune Therapeutics, Inc.
- Shionogi & Co., Ltd.
- GeneOne Life Science, Inc.
- Berlin Cures GmbH
- Resverlogix Corp
- Cocrystal Pharma, Inc.
- Coeptis Therapeutics Holdings, Inc.
- Immorna Biotherapeutics, Inc.
- VBI Vaccines Inc.
- Oneness Biotech Co., Ltd.
- Senhwa Biosciences, Inc.
Key Products
- VYD-2311
- Ibuzatrelvir
- N-803
- ENTVAX002
- RBM001
- MDX2301
- LMN-301
- PA-001
- AZD5156
- HDT-301
- SP0287
- IMNN-101
- KB20V
- EDP-235
- Tonabersat
- VXA-CoV2-3.1
- Rintatolimod
- NE3107
- CVXGA
- AV-001
- S-268019
- GLS-1027
- BC-007
- Apabetalone
- CDI-988
- DVX-201
- JCXH-221
- VBI-2902
- SNS-812
- CX-4945
This product will be delivered within 2-4 business days.
Table of Contents
IntroductionExecutive SummaryCOVID-19- Analytical PerspectiveCOVID-19 Key CompaniesCOVID-19 Key ProductsCOVID-19- Unmet NeedsCOVID-19- Market Drivers and BarriersCOVID-19- Future Perspectives and ConclusionCOVID-19 Analyst ViewsCOVID-19 Key CompaniesAppendix
COVID-19: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
VYD-2311: Invivyd, Inc.
Mid Stage Products (Phase II)
ENTVAX002: Entos Pharmaceuticals Inc.
Early Stage Products (Phase I)
RBM001: Rock BioMedical, Inc.
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Invivyd, Inc.
- Pfizer
- ImmunityBio, Inc.
- Entos Pharmaceuticals Inc.
- Rock BioMedical, Inc.
- OPKO Health, Inc.
- Lumen Bioscience, Inc.
- PeptiDream Inc.
- AstraZeneca
- HDT Bio
- Sanofi
- Imunon
- KBio Inc
- Enanta Pharmaceuticals, Inc
- Inflammx Therapeutics Inc
- Vaxart Inc
- BioVie Inc.
- AIM ImmunoTech Inc.
- CyanVac LLC
- Vasomune Therapeutics, Inc.
- Shionogi & Co., Ltd.
- GeneOne Life Science, Inc.
- Berlin Cures GmbH
- Resverlogix Corp
- Cocrystal Pharma, Inc.
- Coeptis Therapeutics Holdings, Inc.
- Immorna Biotherapeutics, Inc.
- VBI Vaccines Inc.
- Oneness Biotech Co., Ltd.
- Senhwa Biosciences, Inc.
